Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?

① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.

cls.cnMar 27 04:08 ET

Merck And Jiangsu Hengrui Pharmaceuticals Entered Into An Exclusive License Agreement For HRS-5346, An Investigational Oral Small Molecule Lipoprotein(a) Inhibitor Currently In A Phase 2 Trial In China, Hengrui Pharma Will Receive An Upfront Payment...

BenzingaMar 25 06:47 ET

Shanghai Haohai Biological Technology 2024 Annual Report: The proportion of medical aesthetics business has further increased, and the impact of policies such as centralized procurement has not yet faded.

① The medical beauty Sector achieved revenue of 1.195 billion yuan, a year-on-year increase of 13.08%, with the business proportion rising from 39.96% to 44.38%, becoming the core driving force behind the company's current performance growth. ② Compared to the "counter-trend growth" of the medical beauty Sector, multiple sectors of Shanghai Haohai Biological Technology experienced varying degrees of revenue decline, and have not yet overcome the painful adjustment period of policies.

cls.cnMar 22 03:10 ET

The FDA has once again delayed the approval for Jiangsu Hengrui Pharmaceuticals' PD-1 combination product.

Once again, it is a production compliance issue.

wallstreetcnMar 21 07:03 ET

The "Double Ai" therapy has encountered obstacles again in its launch in the USA. Jiangsu Hengrui Pharmaceuticals responded that they will "quickly resubmit the listing application after confirming the reasons."

① The "Double Ai" therapy has received a complete response letter from the FDA upon the second submission of the application; ② Jiangsu Hengrui Pharmaceuticals responded to reporters stating: they will promptly resubmit the application for market approval after confirming the reasons; ③ Experts say, "This is just a minor setback, production-related issues are easy to resolve."

cls.cnMar 21 06:32 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET